Peapod Lane Capital LLC purchased a new stake in FONAR Co. (NASDAQ:FONR - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 142,601 shares of the medical equipment provider's stock, valued at approximately $2,159,000. FONAR accounts for approximately 2.1% of Peapod Lane Capital LLC's investment portfolio, making the stock its 16th biggest position. Peapod Lane Capital LLC owned 2.25% of FONAR as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of FONR. JPMorgan Chase & Co. increased its position in shares of FONAR by 148.3% in the third quarter. JPMorgan Chase & Co. now owns 3,012 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 1,799 shares in the last quarter. Empowered Funds LLC grew its position in FONAR by 5.1% during the 4th quarter. Empowered Funds LLC now owns 19,635 shares of the medical equipment provider's stock worth $297,000 after purchasing an additional 945 shares in the last quarter. Linden Thomas Advisory Services LLC grew its position in FONAR by 15.1% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 29,236 shares of the medical equipment provider's stock worth $443,000 after purchasing an additional 3,837 shares in the last quarter. Corsair Capital Management L.P. raised its stake in FONAR by 8.8% during the 3rd quarter. Corsair Capital Management L.P. now owns 27,972 shares of the medical equipment provider's stock valued at $453,000 after purchasing an additional 2,266 shares during the period. Finally, Inspire Advisors LLC lifted its holdings in shares of FONAR by 21.2% in the third quarter. Inspire Advisors LLC now owns 34,342 shares of the medical equipment provider's stock valued at $556,000 after purchasing an additional 5,998 shares in the last quarter. Hedge funds and other institutional investors own 50.64% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, StockNews.com lowered FONAR from a "strong-buy" rating to a "buy" rating in a research report on Saturday, November 16th.
Check Out Our Latest Report on FONAR
FONAR Trading Down 1.0 %
NASDAQ:FONR traded down $0.16 on Monday, hitting $16.25. 6,403 shares of the company's stock traded hands, compared to its average volume of 12,634. The firm has a 50-day moving average price of $15.49 and a 200-day moving average price of $16.00. The company has a market cap of $102.86 million, a PE ratio of 11.61 and a beta of 1.23. FONAR Co. has a 1 year low of $14.05 and a 1 year high of $24.05.
About FONAR
(
Free Report)
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services.
Featured Articles
Before you consider FONAR, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FONAR wasn't on the list.
While FONAR currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
